Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 32. Отображено 32.
30-05-2017 дата публикации

Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof

Номер: US0009662307B2
Автор: Joseph S. Zakrzewski, ZAKRZEWSKI JOSEPH S, Zakrzewski Joseph S.
Принадлежит: The Regents of the University of Colorado, AMARIN PHARMACEUTICALS IE LTD, UNIV COLORADO REGENTS, Amarin Pharmaceuticals Ireland Limited

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Подробнее
Номер записи: 1
18-05-2017 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF

Номер: US20170136055A1
Автор: Joseph S. Zakrzewski, ZAKRZEWSKI JOSEPH S, Zakrzewski Joseph S.
Принадлежит:

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A composition comprising mipomersen and eicosapentaenoic acid.2. The composition of claim 1 , wherein the composition comprises at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , eicosapentaenoic acid.3. The composition of claim 1 , wherein the mipomersen is present in an amount less than claim 1 , about equal to claim 1 , or greater than an effective amount of mipomersen when administered as a monotherapy.4. The composition of claim 1 , wherein the mipomersen comprises mipomersen nonadecasodium.5. The composition of claim 1 , wherein the mipomersen is suspended in the eicosapentaenoic acid.6. The composition of claim 1 , wherein the mipomersen is in the form of an injectable solution.7. The composition of claim 1 , wherein the composition comprises no more than about 20% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , docosahexaenoic acid or ester thereof.8. The composition of claim 1 , wherein the mipomersen is present in an amount of about 5 mg to about 2000 mg.9. The composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 400 mg to about 5000 mg.10. The composition of claim 1 , wherein the mipomersen is present in an amount of about 2 mg to about 10 mg and the eicosapentaenoic acid is present in an amount of about 400 mg to about 5000 mg.11. A method of treating cardiovascular disease in a subject claim 1 , the method comprising administering to the subject a composition comprising mipomersen and a composition comprising at least about 80% claim 1 , by weight of ail fatty acids (and/or derivatives thereof) present claim 1 , eicosapentaenoic acid.12. The method of claim 11 , wherein the method further comprises identifying the subject as ...

Подробнее
Номер записи: 2
04-05-2017 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF

Номер: US20170119721A1
Автор: Joseph S. Zakrzewski, ZAKRZEWSKI JOSEPH S, Zakrzewski Joseph S.
Принадлежит:

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 19-. (canceled)11. The composition of claim 10 , wherein the composition comprises at least about 80% claim 10 , by weight of all fatty acids present claim 10 , eicosapentaenoate or a pharmaceutically acceptable salt or ester thereof.12. The composition of claim 10 , wherein the hydroxyl compound is present in an amount less than claim 10 , about equal to claim 10 , or greater than an effective amount of the hydroxyl compound when administered as a monotherapy.13. The composition of claim 10 , wherein the hydroxyl compound is present in an amount of about 5 mg to about 2000 mg.14. The composition of claim 10 , wherein the eicosapentaenoate or a pharmaceutically acceptable salt or ester thereof is present in an amount of about 400 mg to about 5000 mg.15: The composition of claim 10 , wherein the hydroxyl compound is dispersed or suspended in the eicosapentaenoate or a pharmaceutically acceptable salt or ester thereof.16. The composition of claim 10 , wherein the hydroxyl compound is 8-hydroxy-2 claim 10 ,2 claim 10 ,14 claim 10 ,14-tetramethylpentadecanedioic acid.18. The method of claim 17 , wherein the cardiovascular-related disease or disorder is hyperlipidemia or homozygous familial hypercholesterolemia (HoFH).19. The method of claim 17 , wherein the subject has a baseline fasting triglyceride level of about 200 mg/dl to about 499 mg/dl.20. The method of claim 18 , wherein the subject is on statin therapy.21. The method of claim 17 , wherein the subject has a baseline fasting triglyceride level of at least about 500 mg/dl.22. The method of claim 17 , wherein the subject is administered the composition for a period of time to effect a reduction in triglyceride levels of at least about 5%.23. The method of claim 22 , wherein the reduction is in comparison to baseline ...

Подробнее
Номер записи: 3
14-11-2017 дата публикации

Compositions comprising EPA and obeticholic acid and methods of use thereof

Номер: US0009814733B2
Автор: Joseph S. Zakrzewski, ZAKRZEWSKI JOSEPH S, Zakrzewski Joseph S.
Принадлежит: A,arin Pharmaceuticals Ireland Limited, AMARIN PHARMACEUTICALS IE LTD, A ARIN PHARMACEUTICALS IRELAND LTD, Amarin Pharmaceuticals Ireland Limited

In various embodiments, the present invention provides compositions comprising eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof. In other embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising co-administering to a subject in need thereof eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof.

Подробнее
Номер записи: 4
27-09-2016 дата публикации

Methods of reducing apolipoprotein C-III

Номер: US0009452151B2
Автор: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski, MANKU MEHAR, OSTERLOH IAN, WICKER PIERRE, BRAECKMAN RENE, SONI PARESH, ZAKRZEWSKI JOSEPH S, Manku Mehar, Osterloh Ian, Wicker Pierre, Braeckman Rene, Soni Paresh, Zakrzewski Joseph S.
Принадлежит: Amarin Pharmaceuticals Ireland Limited, AMARIN PHARMACEUTICALS IE LTD

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 5
02-01-2018 дата публикации

Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof

Номер: US0009855240B2
Автор: Joseph S. Zakrzewski, ZAKRZEWSKI JOSEPH S, Zakrzewski Joseph S.
Принадлежит: Amarin Pharmaceuticals Ireland Limited, AMARIN PHARMACEUTICALS IE LTD

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Подробнее
Номер записи: 6
18-04-2017 дата публикации

Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof

Номер: US0009624492B2
Автор: Joseph S. Zakrzewski, ZAKRZEWSKI JOSEPH S, Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED, AMARIN PHARMACEUTICALS IE LTD, Amarin Pharmaceuticals Ireland Limited

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Подробнее
Номер записи: 7
13-04-2017 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF

Номер: US20170100363A9
Автор: Joseph S. Zakrzewski, ZAKRZEWSKI JOSEPH S, Zakrzewski Joseph S.
Принадлежит: Amarin Pharmaceuticals Ireland Limited

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A composition comprising a hydroxyl compound and ethyl eicosapentaenoate.2. The composition of claim 1 , wherein the composition comprises at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , ethyl eicosapentaenoate.3. The composition of claim 1 , wherein the hydroxyl compound is present in an amount less than claim 1 , about equal to claim 1 , or greater than an effective amount of the hydroxyl compound when administered as a monotherapy.4. The composition of any preceding claim claim 1 , wherein the hydroxyl compound is present in an amount of about 5 mg to about 2000 mg.5. The composition of claim 1 , wherein the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 5000 mg.6. The composition of claim 1 , wherein the hydroxyl compound is dispersed or suspended in the ethyl eicosapentaenoate.7. The composition of claim 1 , wherein the hydroxyl compound is 8-hydroxy-2 claim 1 ,2 claim 1 ,14 claim 1 ,14-tetramethylpentadecanedioic acid.8. A method of treating or preventing a cardiovascular-related disease or disorder in a subject comprising administering to the subject a composition comprising a hydroxyl compound and a composition comprising at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , ethyl eicosapentaenoate.9. The method of claim 8 , wherein the cardiovascular-related disease or disorder is hyperlipidemia or homozygous familial hypercholesterolemia (HoFH).10. The method of claim 8 , wherein the subject has a baseline fasting triglyceride level of about 200 mg/dl to about 499 mg/dl.11. The method of claim 10 , wherein the subject is on statin therapy.12. The method of claim 8 , wherein the subject has a baseline fasting triglyceride ...

Подробнее
Номер записи: 8
12-02-2015 дата публикации

METHODS OF TREATING A CARDIOVASCULAR DISORDER IN A SUBJECT ON APO-C3 MODULATING THERAPY

Номер: US20150045431A1
Автор: Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on Apo-C3 modulating therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject on Apo-C3 modulating therapy , the method comprising administering to the subject a pharmaceutical composition comprising at least about 80% , by weight of all fatty acids (and/or derivatives thereof) present , ethyl eicosapentaenoate.2. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.3. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of at least 500 mg/dl.4. The method of claim 1 , wherein triglycerides are reduced in the subject with no increase in an LDL-C level in the subject.5. The method of claim 4 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline or to a second subject or subject group that has received Apo-C3 modulating therapy but not the ethyl eicosapentaenoate.7. The method of claim 1 , wherein ethyl eicosapentaenoate represents at least about 90% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present.8. The method of claim 7 , wherein ethyl eicosapentaenoate represents at least about 95% claim 7 , by weight of all fatty acids (and/or derivatives thereof) present.9. The method of claim 8 , wherein ethyl eicosapentaenoate represents at least about 96% claim 8 , by weight of all fatty acids (and/or derivatives thereof) present.10. The method of claim 1 , wherein docosahexaenoic acid and its esters represent no more than about 20% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present in the pharmaceutical composition.11. The method of ...

Подробнее
Номер записи: 9
19-02-2015 дата публикации

METHODS OF TREATING A CARDIOVASCULAR DISORDER AND/OR JOINT PAIN IN A SUBJECT ON GLUCOSAMINE THERAPY

Номер: US20150051282A1
Автор: Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on glucosamine therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of treating joint pain in a subject in need thereof , the method comprising administering to the subject a pharmaceutical composition comprising at least about 80% , by weight of all fatty acids (and/or derivatives thereof) present , ethyl eicosapentaenoate.2. The method of claim 1 , wherein the joint pain is associated with osteoarthritis.3. The method of claim 1 , wherein the subject is on glucosamine therapy.4. The method of claim 1 , wherein triglycerides are reduced in the subject with no increase in an LDL-C level in the subject.5. The method of claim 4 , wherein the subject has a fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.6. The method of claim 5 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline claim 5 , or in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl that has received glucosamine but not the ethyl eicosapentaenoate.7. The method of claim 4 , wherein the subject has a fasting baseline triglyceride level of at least 500 mg/dl.8. The method of claim 7 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline claim 7 , or in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of at least 500 mg/dl that has received glucosamine but not the ethyl eicosapentaenoate.9. The method of claim 1 , wherein ethyl ...

Подробнее
Номер записи: 10
05-03-2015 дата публикации

METHODS OF TREATING OR PREVENTING PROSTATE CANCER

Номер: US20150065572A1
Автор: Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of treating or preventing prostate cancer in a subject , the method comprising administering to the subject a pharmaceutical composition comprising at least about 80% , by weight of all fatty acids (and/or derivatives thereof) present , ethyl eicosapentaenoate.2. The method of claim 1 , wherein triglycerides are reduced in the subject with no increase in an LDL-C level in the subject.3. The method of claim 2 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline claim 2 , or in comparison to a second subject or subject group that has received a prostate cancer therapy but not the ethyl eicosapentaenoate.4. The method of claim 1 , wherein ethyl eicosapentaenoate represents at least about 90% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present.5. The method of claim 1 , wherein docosahexaenoic acid and its esters represent no more than about 20% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present in the pharmaceutical composition.6. The method of claim 1 , wherein the subject has a risk factor associated with prostate cancer.7. The method of claim 6 , wherein the risk factor is selected from the group consisting of: a genetic risk factor claim 6 , a family history risk factor claim 6 , a dietary risk factor claim 6 , a viral risk factor claim 6 , a sexual-related risk factor claim 6 , a risk factor associated with exposure to medication claim 6 , and a risk factor associated with a medical procedure.8. The method of claim 7 , wherein the genetic risk factor comprises a mutation in BRCA1 claim 7 , a mutation in BRCA2 claim 7 , a mutation in HPC1 claim 7 , a mutation in the androgen ...

Подробнее
Номер записи: 11
08-03-2018 дата публикации

METHODS OF TREATING OR PREVENTING PROSTATE CANCER

Номер: US20180064676A1
Автор: Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 120.-. (canceled)21. A method of treating prostate cancer in a subject having an elevated PSA level , the method comprising administering a pharmaceutical composition comprising ethyl eicosapentaenoate to the subject for a period of time effective to reduce the subject's PSA level by at least 50%.22. The method of claim 21 , wherein triglycerides are reduced in the subject with no increase in an LDL-C level in the subject.23. The method of claim 22 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline claim 22 , or in comparison to a second subject or subject group that has received a prostate cancer therapy but not the ethyl eicosapentaenoate.24. The method of claim 21 , wherein ethyl eicosapentaenoate represents at least 90% claim 21 , by weight of all fatty acids (and/or derivatives thereof) present.25. The method of claim 21 , wherein docosahexaenoic acid and its esters represent no more than 20% claim 21 , by weight of all fatty acids (and/or derivatives thereof) present in the pharmaceutical composition.26. The method of claim 21 , wherein the subject has a risk factor associated with prostate cancer.27. The method of claim 26 , wherein the risk factor is selected from the group consisting of: a genetic risk factor claim 26 , a family history risk factor claim 26 , a dietary risk factor claim 26 , a viral risk factor claim 26 , a sexual-related risk factor claim 26 , a risk factor associated with exposure to medication claim 26 , and a risk factor associated with a medical procedure.28. The method of claim 27 , wherein the genetic risk factor comprises a mutation in BRCA1 claim 27 , a mutation in BRCA2 claim 27 , a mutation in HPC1 ...

Подробнее
Номер записи: 12
12-03-2015 дата публикации

CO-ADMINISTRATION OF OMEPRAZOLE AND EICOSAPENTAENOIC ACID OR A DERIVATIVE THEREOF

Номер: US20150073050A1
Автор: Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on omeprazole therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing triglycerides in a subject on omeprazole therapy , the method comprising administering to the subject a pharmaceutical composition comprising at least about 80% , by weight of all fatty acids (and/or derivatives thereof) present , ethyl eicosapentaenoate.2. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.3. The method of claim 2 , wherein the reduction in triglycerides is in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of about 200 mg/dl to 499 mg/dl.4. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of at least 500 mg/dl.5. The method of claim 4 , wherein the reduction in triglycerides is in comparison to a second subject or second subject group having a fasting baseline triglyceride level or a mean or median fasting baseline triglyceride level of at least 500 mg/dl.6. The method of claim 1 , wherein triglycerides are reduced in the subject with no increase in an LDL-C level in the subject.7. The method of claim 6 , wherein the reduction in triglycerides and the no increase in LDL-C level is in comparison to baseline or to a second subject or subject group that has received omeprazole but not the ethyl eicosapentaenoate.8. The method of claim 1 , wherein ethyl eicosapentaenoate represents at least about 90% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present.9. The method of claim 1 , wherein docosahexaenoic acid and its esters represent no ...

Подробнее
Номер записи: 13
14-03-2019 дата публикации

Methods of Reducing Apolipoprotein C-III

Номер: US20190076390A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing an APOC3 level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day ,wherein the subject is on a high statin efficacy regimen selected from the group consisting of about 20 to about 40 mg rosuvastatin, about 40 to about 80 mg atorvastatin, about 80 mg simvastatin, and about 40 to about 80 mg simvastatin plus about 5 to about 10 mg ezetimibe or the subject is on a medium statin efficacy regimen selected from the group consisting of about 5 to about 10 mg rosuvastatin, about 10 to about 20 mg atorvastatin, about 20 to about 40 mg simvastatin, and about 10 to about 20 mg simvastatin plus about 5 to about 10 mg ezetimibe.2. The method of claim 1 , wherein the APOC3 level is reduced by at least about 5%.3. The method of claim 1 , wherein the APOC3 level is reduced by at least about 15%.4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.7. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.8. The method of claim 1 , wherein the ...

Подробнее
Номер записи: 14
21-03-2019 дата публикации

METHODS OF REDUCING APOLIPOPROTEIN C-III

Номер: US20190083444A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing an APOC3 level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.2. The method of claim 1 , wherein the APOC3 level is reduced by at least about 5%.3. The method of claim 1 , wherein the APOC3 level is reduced by at least about 15%.4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.7. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.8. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.9. The method of claim 1 , wherein the pharmaceutical composition comprises no more than about 10% claim 1 , by weight of all fatty acids present claim 1 , docosahexaenoic acid or a derivative thereof claim 1 , if any.10. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate and no more than about 2% claim ...

Подробнее
Номер записи: 15
05-05-2016 дата публикации

Methods of reducing apolipoprotein C-III

Номер: US20160120837A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing an APOC3 level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.2. The method of claim 1 , wherein the APOC3 level is reduced by at least about 5%.3. The method of claim 1 , wherein the APOC3 level is reduced by at least about 15%.4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.7. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.8. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl cicosapentaenoate.9. The method of claim 1 , wherein the pharmaceutical composition comprises no more than about 10% claim 1 , by weight of all fatty acids present claim 1 , docosahexaenoic acid or a derivative thereof claim 1 , if any.10. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate and no more than about 2% claim ...

Подробнее
Номер записи: 16
07-08-2014 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND DIAZOXIDE AND METHODS OF USE THEREOF

Номер: US20140221358A1
Автор: Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A composition comprising diazoxide and ethyl eicosapentaenoate.2. The composition of claim 1 , wherein the diazoxide is suspended in the ethyl eicosapentaenoate.3. The composition of claim 2 , wherein the diazoxide is in the form of a solid dosage form.4. The composition of claim 1 , wherein the composition comprises at least about 80% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.5. The composition of claim 4 , wherein the composition comprises at least about 90% claim 4 , by weight of all fatty acids present claim 4 , ethyl eicosapentaenoate.6. The composition of claim 1 , wherein the composition comprises no more than about 20% claim 1 , by weight of all fatty acids present claim 1 , docosahexaenoate or ester thereof.7. The composition of claim 1 , wherein the diazoxide is present in an amount of about 5 mg to about 300 mg and the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 5000 mg.8. A method of treating or preventing a cardiovascular-related disease or disorder in a subject comprising administering to the subject a composition comprising diazoxide and ethyl eicosapentaenoate.9. The method of claim 8 , wherein the cardiovascular-related disease or disorder is hyperlipidemia or mixed dyslipidemia.10. The method of claim 8 , wherein the subject has a baseline fasting triglyceride level of about 200 mg/dl to about 499 mg/dl.11. The method of claim 10 , wherein the subject is on statin therapy.12. The method of claim 8 , wherein the subject has a baseline fasting triglyceride level of at least about 500 mg/dl.13. The method of claim 8 , wherein the composition comprises at least about 90% claim 8 , by weight of all fatty acids present claim 8 , ethyl eicosapentaenoate.14. The method of claim 8 , wherein ...

Подробнее
Номер записи: 17
07-08-2014 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND 5-HTP AND METHODS OF USE THEREOF

Номер: US20140221452A1
Автор: Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A composition comprising 5-HTP and ethyl eicosapentaenoate.2. The composition of claim 1 , wherein the 5-HTP is suspended in the ethyl eicosapentaenoate.3. The composition of claim 4 , wherein the 5-HTP is in the form of a solid dosage form.4. The composition of claim 1 , wherein the composition comprises at least about 80% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.5. The composition of claim 1 , wherein the composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.6. The composition of claim 1 , wherein the composition comprises no more than about 20% claim 1 , by weight of all fatty acids present claim 1 , docosahexaenoate or ester thereof.7. The composition of claim 1 , wherein the 5-HTP is present in an amount of about 50 mg to about 800 mg and the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 5000 mg.8. A method of treating or preventing a cardiovascular-related disease or disorder in a subject comprising administering to the subject a composition comprising 5-HTP and a composition comprising at least about 80% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.9. The method of claim 8 , wherein the cardiovascular-related disease or disorder is hyperlipidemia or mixed dyslipidemia.10. The method of claim 8 , wherein the subject has a baseline fasting triglyceride level of about 200 mg/dl to about 499 mg/dl.11. The method of claim 10 , wherein the subject is on statin therapy.12. The method of claim 8 , wherein the subject has a baseline fasting triglyceride level of at least about 500 mg/dl.13. The method of claim 8 , wherein the composition comprises at least about 90% claim 8 , by weight of all fatty ...

Подробнее
Номер записи: 18
07-08-2014 дата публикации

METHODS OF REDUCING APOLIPOPROTEIN C-III

Номер: US20140221486A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing an APOC3 level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.2. The method of claim 1 , wherein the APOC3 level is reduced by at least about 5%.3. The method of claim 1 , wherein the APOC3 level is reduced by at least about 15%.4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.7. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.8. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.9. The method of claim 1 , wherein the pharmaceutical composition comprises no more than about 10% claim 1 , by weight of all fatty acids present claim 1 , docosahexaenoic acid or a derivative thereof claim 1 , if any.10. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate and no more than about 2% claim ...

Подробнее
Номер записи: 19
26-05-2016 дата публикации

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OBESITY IN A SUBJECT IN NEED THEREOF

Номер: US20160143875A1
Автор: Zakrzewski Joseph S.
Принадлежит:

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity. 1. A method of treating and/or preventing obesity in a subject comprising , administering to the subject a pharmaceutical composition comprising about 2500 mg to 5000 mg per day of ethyl eicosapentaenoate and not more than about 5% docosahexaenoic acid or its esters , by weight of all fatty acids , to effect a reduction in one or more of: BMI , body weight , waist measurement , and body fat percentage.2. The method of wherein the reduction is compared to baseline.3. The method of wherein the reduction is compared to placebo arm.4. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in any one or more of: BMI claim 1 , body weight claim 1 , waist measurement claim 1 , and body fat percentage of at least 5% claim 1 , at least 10% claim 1 , at least 15% claim 1 , or at least 20% compared to baseline or placebo control.5. The method of wherein upon 12 weeks of said administration the subject exhibits a reduction in fasting triglycerides of at least 25% compared to placebo control6. The method of wherein the subject further exhibits a reduction in one or more of: fasting triglycerides claim 1 , fasting LDL-C claim 1 , fasting apolipoprotein B claim 1 , hs-CRP claim 1 , non-HDL-C claim 1 , fasting VLDL-C claim 1 , oxidized LDL claim 1 , lipoprotein associated phospholipase A2 claim 1 , and total cholesterol claim 1 , compared to baseline or placebo control.7. The method of wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 500 mg to about 1.5 g of ethyl eicosapentaenoate.8. The method of wherein the dosage units are capsules.9. The method of wherein the ethyl eicosapentaenoate is administered to the subject in dosage units each comprising about 900 mg to about 1 g of ethyl eicosapentaenoate.10. The method ...

Подробнее
Номер записи: 20
28-08-2014 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF

Номер: US20140243389A1
Автор: Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A composition comprising mipomersen and ethyl eicosapentaenoate.2. The composition of claim 1 , wherein the composition comprises at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , ethyl eicosapentaenoate.3. The composition of claim 1 , wherein the mipomersen is present in an amount less than claim 1 , about equal to claim 1 , or greater than an effective amount of mipomersen when administered as a monotherapy.4. The composition of claim 1 , wherein the mipomersen comprises mipomersen nonadecasodium.5. The composition of claim 1 , wherein the mipomersen is suspended in the ethyl eicosapentaenoate.6. The composition of claim 1 , wherein the mipomersen is in the form of an injectable solution.7. The composition of claim 1 , wherein the composition comprises no more than about 20% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , docosahexaenoate or ester thereof.8. The composition of claim 1 , wherein the mipomersen is present in an amount of about 5 mg to about 2000 mg.9. The composition of claim 1 , wherein the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 5000 mg.10. The composition of claim 1 , wherein the mipomersen is present in an amount of about 2 mg to about 10 mg and the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 5000 mg.11. A method of treating or preventing a cardiovascular-related disease or disorder in a subject comprising administering to the subject a composition comprising mipomersen and a composition comprising at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , ethyl eicosapentaenoate.12. The method of claim 11 , wherein the cardiovascular-related ...

Подробнее
Номер записи: 21
11-09-2014 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF

Номер: US20140256809A1
Автор: Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.

Подробнее
Номер записи: 22
18-09-2014 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND KRILL OIL AND METHODS OF USE THEREOF

Номер: US20140271907A1
Автор: Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A composition comprising:krill oil; anda fatty acid component comprising ethyl eicosapentaenoate.2. The composition of claim 1 , wherein the fatty acid component comprises at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present in the fatty acid component claim 1 , ethyl eicosapentaenoate.3. The composition of claim 1 , wherein the krill oil is present in an amount less than claim 1 , about equal to claim 1 , or greater than an effective amount of krill oil when administered as a monotherapy.4. The composition of claim 1 , wherein the krill oil is comprises EPA and DHA.5. The composition of claim 1 , wherein the krill oil is suspended in the ethyl eicosapentaenoate.6. The composition of claim 1 , wherein the fatty acid component comprises at least about 95% claim 1 , by weight of all fatty acids (and/or derivatives thereof) presenting the fatty acid component claim 1 , ethyl eicosapentaenoate.7. The composition of claim 1 , wherein the fatty acid component comprises no more than about 20% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present in the fatty acid component claim 1 , docosahexaenoate or ester thereof.8. The composition of claim 1 , wherein the fatty acid component comprises no more than about 1% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , of any single fatty acid other than ethyl eicosapentaenoate.9. The composition of claim 1 , wherein the krill oil is present in an amount of about 5 mg to about 3000 mg.10. The composition of claim 1 , wherein the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 5000 mg.11. The composition of claim 10 , wherein the ethyl eicosapentaenoate is present in an amount of about 400 mg to about 600 mg.12 ...

Подробнее
Номер записи: 23
18-09-2014 дата публикации

METHODS OF TREATING TRAUMATIC BRAIN INJURY

Номер: US20140275252A1
Автор: Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent traumatic brain injuries. 1. A method of treating traumatic brain injury in a subject in need thereof , the method comprising administering to the subject a composition comprising at least about 80% , by weight of all fatty acids and/or derivatives thereof present , ethyl eicosapentaenoate.2. The method of claim 1 , wherein the composition comprises no more than about 5% claim 1 , by weight of all fatty acids and/or derivatives thereof present claim 1 , docosahexaenoic acid or esters thereof.3. The method of claim 1 , wherein the composition comprises at least about 90% claim 1 , by weight of all fatty acids and/or derivatives thereof present claim 1 , ethyl eicosapentaenoate.4. The method of claim 3 , wherein the composition comprises at least about 95% claim 3 , by weight of all fatty acids and/or derivatives thereof present claim 3 , ethyl eicosapentaenoate.5. The method of claim 4 , wherein the composition comprises at least about 96% claim 4 , by weight of all fatty acids and/or derivatives thereof present claim 4 , ethyl eicosapentaenoate.6. The method of claim 1 , wherein the composition is administered for a period of time to effect an improvement in one or more of: motor function claim 1 , fine motor function claim 1 , Glasgow Coma Score (“GCS”) claim 1 , eye response component of GCS claim 1 , motor response component of GCS claim 1 , and verbal response component of GCS.7. The method of claim 6 , wherein the improvement is in Glasgow Coma Score.8. The method of claim 7 , wherein the improvement in Glasgow Coma Score is at least 2 claim 7 , at least 3 claim 7 , at least 4 claim 7 , at least 5 claim 7 , at least 6 claim 7 , at least 7 claim 7 , at least 8 claim 7 , at least 9 claim 7 , or at least 10.9. The method of claim 6 , wherein the improvement is in eye response component of GCS.10. The ...

Подробнее
Номер записи: 24
18-09-2014 дата публикации

Compositions and methods for treating or preventing obesity in a subject in need thereof

Номер: US20140275253A1
Автор: Joseph S. Zakrzewski
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity.

Подробнее
Номер записи: 25
06-08-2015 дата публикации

Methods of Reducing Apolipoprotein C-III

Номер: US20150216831A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит: AMARIN PHARMACEUTICALS IRELAND LIMITED

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 1. A method of reducing an APOC3 level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of ethyl eicosapentaenoate per day.2. The method of claim 1 , wherein the APOC3 level is reduced by at least about 5%.3. The method of claim 1 , wherein the APOC3 level is reduced by at least about 15%.4. The method of claim 1 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.5. The method of claim 1 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.6. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.7. The method of claim 1 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.8. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate.9. The method of claim 1 , wherein the pharmaceutical composition comprises no more than about 10% claim 1 , by weight of all fatty acids present claim 1 , docosahexaenoic acid or a derivative thereof claim 1 , if any.10. The method of claim 1 , wherein the pharmaceutical composition comprises at least about 95% claim 1 , by weight of all fatty acids present claim 1 , ethyl eicosapentaenoate and no more than about 2% claim ...

Подробнее
Номер записи: 26
25-06-2020 дата публикации

METHODS OF REDUCING APOLIPOPROTEIN C-III

Номер: US20200197350A1
Автор: Braeckman Rene, Manku Mehar, Osterloh Ian, Soni Paresh, Wicker Pierre, Zakrzewski Joseph S.
Принадлежит:

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. 120-. (canceled)21. A method of reducing an apolipoprotein C3 (APOC3) level of a subject on statin therapy and having baseline fasting triglycerides of about 200 mg/dl to about 499 mg/dl , the method comprising administering to the subject a pharmaceutical composition comprising ethyl eicosapentaenoate and docosapentaenoic acid.22. The method of claim 21 , wherein the APOC3 level is reduced by at least about 5%.23. The method of claim 21 , wherein the APOC3 level is reduced by at least about 15%.24. The method of claim 21 , wherein about 1 g to about 4 g of ethyl eicosapentaenoate is administered to the subject per day.25. The method of claim 24 , wherein about 2 g per day of ethyl eicosapentaenoate is administered to the subject.26. The method of claim 24 , wherein about 3.8 g to about 4 g per day of ethyl eicosapentaenoate is administered to the subject.27. The method of claim 21 , wherein the pharmaceutical composition is administered to the subject daily for a period of 1 to about 12 weeks.28. The method of claim 21 , wherein the reduction in APOC3 level is in comparison to control subjects having fasting triglycerides of about 200 mg/dl to about 499 mg/dl who have received the statin but not the pharmaceutical composition.29. The method of claim 21 , wherein the pharmaceutical composition comprises at least about 95% claim 21 , by weight of all fatty acids present claim 21 , ethyl eicosapentaenoate.30. The method of claim 21 , wherein the pharmaceutical composition comprises no more than about 10% claim 21 , by weight of all fatty acids present claim 21 , docosapentaenoic acid or a derivative thereof claim 21 , if any.31. The method of claim 21 , ...

Подробнее
Номер записи: 27
11-12-2014 дата публикации

Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof

Номер: US20140364459A1
Автор: Joseph S. Zakrzewski
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on rosiglitazone therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 28
17-10-2019 дата публикации

COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF

Номер: US20190316122A1
Автор: Zakrzewski Joseph S.
Принадлежит:

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. 1. A composition comprising mipomersen and eicosapentaenoic acid.2. The composition of claim 1 , wherein the composition comprises at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , eicosapentaenoic acid.3. The composition of claim 1 , wherein the mipomersen is present in an amount less than claim 1 , about equal to claim 1 , or greater than an effective amount of mipomersen when administered as a monotherapy.4. The composition of claim 1 , wherein the mipomersen comprises mipomersen nonadecasodium.5. The composition of claim 1 , wherein the mipomersen is suspended in the eicosapentaenoic acid.6. The composition of claim 1 , wherein the mipomersen is in the form of an injectable solution.7. The composition of claim 1 , wherein the composition comprises no more than about 20% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , docosahexaenoic acid or ester thereof.8. The composition of claim 1 , wherein the mipomersen is present in an amount of about 5 mg to about 2000 mg.9. The composition of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 400 mg to about 5000 mg.10. The composition of claim 1 , wherein the mipomersen is present in an amount of about 2 mg to about 10 mg and the eicosapentaenoic acid is present in an amount of about 400 mg to about 5000 mg.11. A method of treating cardiovascular disease in a subject claim 1 , the method comprising administering to the subject a composition comprising mipomersen and a composition comprising at least about 80% claim 1 , by weight of all fatty acids (and/or derivatives thereof) present claim 1 , eicosapentaenoic acid.12. The method of claim 11 , wherein the method further comprises identifying the subject as ...

Подробнее
Номер записи: 29
08-10-2020 дата публикации

Methods of Reducing Apolipoprotein C-III

Номер: US20200316006A1
Автор: Ian OSTERLOH, Joseph S. Zakrzewski, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 30
19-02-2019 дата публикации

Compositions and methods for treating or preventing obesity in a subject in need thereof

Номер: US10206898B2
Автор: Joseph S. Zakrzewski
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity.

Подробнее
Номер записи: 31
20-05-2021 дата публикации

Methods of treating or preventing prostate cancer

Номер: US20210145786A1
Автор: Joseph S. Zakrzewski
Принадлежит: Amarin Pharmaceuticals Ireland Ltd

In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 32